PROTACs
-
PROTACs Related Products (428)
Related Products (428)
-
dBET6 (Standard)
0 ImagesCat. No.: HY-112588RCAS No.: 1950634-92-0
-
CRBN ligand-186
0 ImagesCat. No.: HY-174249CAS No.: 3084710-09-5
-
PROTAC Sirt2 Degrader-1 (Standard)
0 ImagesCat. No.: HY-103636RCAS No.: 2098487-75-1PROTAC Sirt2 Degrader-1 (Standard) is the analytical standard of PROTAC Sirt2 Degrader-1 (HY-103636). This product is intended for research and analytical applications. PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC, acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide Cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1/Sirt3 (IC50s>100 μM).
-
BMS-986365 (Standard)
0 ImagesCat. No.: HY-158101RCAS No.: 2446928-30-7Synonyms: CC-94676 (Standard)BMS-986365 (Standard) is the analytical standard of BMS-986365 (HY-158101). This product is intended for research and analytical applications. BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC50 of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC).
-
vRNPs degrader-1
0 ImagesCat. No.: HY-177791vRNPs degrader-1 is a potent PROTAC viral ribonucleoproteins (vRNPs) degrader. vRNPs degrader-1 shows broad-spectrum anti-influenza A viruses (IAV) activity by targeting the conserved 5′ end of viral RNA, thereby inducing proteasomal degradation of viral proteins. vRNPs degrader-1 inhibits H1N1, H9N2, and H3N2 infection in mice. vRNPs degrader-1 can be used for influenza research.
-
BI-3663 (Standard)
0 ImagesCat. No.: HY-111546RCAS No.: 2341740-84-7BI-3663 (Standard) is the analytical standard of BI-3663 (HY-111546). This product is intended for research and analytical applications. BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker. Anti-cancer activity.
-
PROTAC SARS-CoV-2 Mpro degrader-3
0 ImagesCat. No.: HY-161789PROTAC SARS-CoV-2 Mpro degrader-3 is a SARS-CoV-2 Mpro PROTAC degrader with a DC50 of 27 μM in HEK 293T cells. It also acts as an inhibitor of HCoV-229E, HCoV-OC43 and SARS-CoV-2 Mpro, with an IC50 of 0.748 μM and a Kd of 37 μM against SARS-CoV-2 Mpro. PROTAC SARS-CoV-2 Mpro degrader-3 forms a ternary complex with purified SARS-CoV-2 Mpro and VCB E3 ligase to induce intracellular protease degradation. It reduces coronavirus replication and can be used in research on coronavirus infections.
-
rG4 mut_AHPC_PEG2
0 ImagesCat. No.: HY-185724rG4 mut_AHPC_PEG2 is a structure-disruptive negative control PROTAC. rG4 mut_AHPC_PEG2 demonstrates that the RNA G-quadruplex conformation is an absolute prerequisite for the recruitment and degradation of DHX36 by retaining the E3-recruiting moiety (AHPC-PEG2) while disrupting the secondary structure of the nucleic acid moiety (mutated RNA G-quadruplex),.
-
PROTAC HIV-1 degrader-1
0 ImagesCat. No.: HY-187361CAS No.: 3107740-33-7PROTAC HIV-1 degrader-1 is a HIV-1 capsid (CA) PROTAC degrader, with a DC50 of 3 nM against HIV-1IIIB (MT‑4 cells) and a DC50 of 1.17 nM against HIV-1NL4-3 (MT‑4 cells). PROTAC HIV-1 degrader-1 conjugates HIV-1 capsid (CA) with the VHL E3 ubiquitin ligase, triggering polyubiquitination and proteasome-mediated degradation of CA, as well as competitively inhibiting the binding of host factors CPSF6 and Sec24C to CA. PROTAC HIV-1 degrader-1 degrades CA drug-resistant mutants (N74D, K70R). PROTAC HIV-1 degrader-1 is applicable to research related to HIV-1 infection.
-
Vepdegestrant (Standard)
0 ImagesCat. No.: HY-138642RCAS No.: 2229711-68-4Synonyms: ARV-471 (Standard); PF-07850327 (Standard)Vepdegestrant (Standard) is the analytical standard of Vepdegestrant (HY-138642). This product is intended for research and analytical applications. Vepdegestrant (ARV-471) is an orally active PROTAC estrogen receptor degrader against breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a half-maximal degradation concentration (DC50) of about 2 nM.
-
RPG-01-132
0 ImagesCat. No.: HY-181920RPG-01-132 is a PROTAC degrader targeting the DENV capsid protein, with a DC50 of 2.4 μM. RPG-01-132 blocks viral assembly, eliminates viral particles, and interferes with the non-structural functions of the capsid protein. RPG-01-132 exhibits significant antiviral activity against all four DENV serotypes and the ST148 (HY-121663)-resistant DENV2 mutant strain. RPG-01-132 can be applied in studies related to dengue virus infection.
-
MZ 1 (Standard)
0 ImagesCat. No.: HY-107425RCAS No.: 1797406-69-9MZ 1 (Standard) is the analytical standard of MZ 1 (HY-107425). This product is intended for research and analytical applications. MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. Kds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively.
-
JH-XI-10-02 (Standard)
0 ImagesCat. No.: HY-111518RCAS No.: 2209085-22-1JH-XI-10-02 (Standard) is the analytical standard of JH-XI-10-02 (HY-111518). This product is intended for research and analytical applications. JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC50 of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19.
-
Bavdegalutamide (Standard)
0 ImagesCat. No.: HY-138641RCAS No.: 2222112-77-6Synonyms: ARV-110 (Standard)Bavdegalutamide (Standard) is the analytical standard of Bavdegalutamide (HY-138641). This product is intended for research and analytical applications. Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer (Pink: AR ligand (HY-168299); Blue: E3 ligase ligand (HY-W093272); Black: linker (HY-W091986)).
-
PROTAC CDK9 Degrader-1 (Standard)
0 ImagesCat. No.: HY-103628RCAS No.: 2118356-96-8
-
dBET1 (Standard)
0 ImagesdBET1 (Standard) is the analytical standard of dBET1 (HY-101838). This product is intended for research and analytical applications. dBET1 is a PROTAC connected by ligands for Cereblon and BRD4 with an EC50 of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker.
-
PROTAC BET Degrader-1 (Standard)
0 ImagesCat. No.: HY-103633RCAS No.: 2093386-22-0PROTAC BET Degrader-1 (Standard) is the analytical standard of PROTAC BET Degrader-1 (HY-103633). This product is intended for research and analytical applications. PROTAC BET Degrader-1 is a BRD2/BRD3/BRD4 PROTAC degrader. PROTAC BET Degrader-1 inhibits the growth of acute leukemia cells. PROTAC BET Degrader-1 is applicable to the research of acute leukemia.
-
PROTAC HBeAg degrader-1
0 ImagesCat. No.: HY-174856PROTAC HBeAg degrader-1 is a HBeAg-targeting PROTAC degrader that recruits VHL. PROTAC HBeAg degrader-1 degrades HBeAg and reduces HBcAg levels in a largely VHL-independent manner, and inhibits secreted HBeAg in a concentration-dependent manner, with particularly stronger inhibitory activity against the HAP-resistant (HBVT109I mutation) strain. PROTAC HBeAg degrader-1 can be used in studies related to hepatitis B virus infection.
